Indiana · 2025 Regular Session · Bill
SB 514: Chimeric antigen receptor T-cell therapy.
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
SB 514 is a bill introduced in the Indiana Senate on January 16, 2025. According to its official title, it concerns: Chimeric antigen receptor T-cell therapy. Primary sponsor: Jean Leising (Republican). Most recent recorded action (January 16, 2025): First reading: referred to Committee on Health and Provider Services.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Official summary
Abstract published by the legislature (via Open States). Text as published by the legislature; reproduced verbatim.
Provides that a policy of accident and sickness insurance or health maintenance organization contract that provides coverage for chimeric antigen receptor (CAR) T-cell therapy may not refuse to contract or deny coverage for the administration of any CAR T-cell therapy by any provider that qualifies as a certified health care facility by the federal Food and Drug Administration for the applicable CAR T-cell therapy.
Sponsors
Sponsors by party (alphabetical): Republican 1
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Jean Leising | Primary sponsor | Republican | Senate | 42 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- First reading: referred to Committee on Health and Provider Services
- Authored by Senator Leising